Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;16(2):164-174.
doi: 10.2174/2589977515666230822114324.

Neoteric Role of Quercetin in Visual Disorders

Affiliations
Review

Neoteric Role of Quercetin in Visual Disorders

Noor Hassan Sulaiman Khil et al. Curr Drug Res Rev. 2024.

Abstract

Flavonoids are a family of secondary metabolites found in plants and fungi that exhibit strong antioxidant properties and low toxicity, making them potential candidates for medicinal use. Quercetin, a flavonoid present in various plant-based foods, has gained attention for its numerous biological benefits, including anti-inflammatory, anti-fibrosis, and antioxidant properties. The ocular surface research community has recently focused on quercetin's therapeutic potential for managing ocular diseases, such as dry eye, keratoconus, corneal inflammation, and neovascularization. In this paper, we discuss the role of quercetin for ocular disease prevention, highlighting its fundamental characteristics, common biological properties, and recent applications. By reviewing the latest research conducted in the last 10 years which was focused on novel herbal formulations for ocular diseases, we aim to provide insights into the role of quercetin in managing ocular diseases and offer perspectives on its potential as a therapeutic agent.

Keywords: Quercetin; applications of quercetin in visual disorders; flavonoid; neoteric.; ocular disease; ocular drug delivery system.

PubMed Disclaimer

References

    1. Stevens G.A.; White R.A.; Flaxman S.R.; Global prevalence of vision impairment and blindness: Magnitude and temporal trends, 1990-2010. Ophthalmology 2013,120(12),2377-2384 - DOI - PubMed
    1. Bodor N.; Buchwald P.; Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J 2005,7(4),E820-E833 - DOI - PubMed
    1. Coroi M.C.; Bungau S.; Tit M.; Preservatives from the eye drops and the ocular surface. Rom J Ophthalmol 2015,59(1),2-5 - PubMed
    1. Baranowski P.; Karolewicz B.; Gajda M.; Pluta J.; Ophthalmic drug dosage forms: Characterisation and research methods. ScientificWorldJournal 2014,2014,1-14 - DOI - PubMed
    1. Parasuraman S.; Anand David A.V.; Arulmoli R.; Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev 2016,10(20),84-89 - DOI - PubMed

LinkOut - more resources